Current Issue

View Larger Image

Past Issues Free Subscriptions
Sponsored
Keywords



Search Results - Shire
 More »

  • Nimbus, Shire Collaborate to Co-Develop Small Molecule Treatments
    Nimbus Discovery has entered a co-development agreement with Shire focused on small molecule treatments for lysosomal storage disorders (LSDs), the firm said. Nimbus and Shire hope ...
    5-8-2013
  • Single-Use Bioreactor Roundup
    ... Also, companies are now bringing on line single-use plants, as recently announced by Shire, and are beginning to utilize bioreactors. Geographically, we are seeing growth in all ...
    4-15-2013
  • Top 20 Best-Selling Drugs Approved and Launched During 2012
    ... 1, 2012, citing the EU market exclusivity until 2020 of a competing agent from Shire #10. Linzess(tm) (linaclotide) 2012 sales: $19.2 million 9 Marketer(s): Ironwood ...
    4-4-2013
  • Shire Buys SARcode Bioscience for $160M+
    Shire said today it will acquire drug developer SARcode Bioscience, in a $160 million-plus ... Shire will pay SARcode Bioscience $160 million up-front, plus additional payments to be ...
    3-25-2013
  • Shire Expands Into Neonatology with Premacure Acquisition
    therapeutic offerings into neonatology, Shire said today it is buying Swedish-owned ... The price was not disclosed, although Shire said it will acquire Premacure for an up-front ...
    3-12-2013
  • Adderall Generics and Legal Woes Hurt Shire
    Shire profits during the fourth quarter of 2012-though the company says it is in strong shape this year following investments in late-stage pipeline drug candidates. Shire saw ...
    2-14-2013
  • Shire Acquires Lotus Tissue Repair
    Shire said today it will acquire Lotus Tissue Repair, the privately-held developer of the ... The price was not disclosed, though Shire said it would make an up-front payment as well ...
    1-8-2013
  • GPCRs Targeted in Heptares/Cubist Collab
    Also, in March of last year, Shire made a potentially $190 million deal with Heptares for an exclusive worldwide license to Heptares' adenosine A 2A receptor antagonist candidate ...
    1-7-2013
  • Shire Rare-Disease Partnerships Expand
    Shire today broadened its research partnership efforts aimed at rare disease, launching a ... Under the alliance with German-owned ethris, Shire will develop mABs using its partner's ...
    1-7-2013
  • The New Economics of Orphan Diseases
    ... Shire is among them. It formed a strategic collaboration with Sangamo BioSciences in ... Shire also is developing therapeutics for mucopolysaccharidosis type II (Hunter syndrome), ...
    1-1-2013
  • People in the News
    M.D. Jeff Jonas, M.D. , is now president of regenerative medicine business at Shire. Formerly, he was leader of the specialty pharmaceuticals R&D team. Before joining Shire, Dr. ...
    1-1-2013
  • Shire, Arrowhead Launch PDC Collaboration
    Shire will use the human-derived Homing Peptide platform of Arrowhead Research to develop ... "With this novel platform technology, Shire has the potential to move into a wider ...
    12-18-2012
  • Top 14 Abused Prescription Drugs
    ... expire 2014. #6. Adderall XR (amphetamine/dextroamphetamine) Maker of brand-name drug: Shire 2011 sales: $533 million 2010 sales: $361 million % Change: 47.6% Indication: ...
    12-10-2012
  • Pfizer, Protalix Beef Up Gaucher Disease Partnership
    Protalix will continue to manage, administer, and sponsor current, ongoing adult and pediatric extension studies of clinical trials relating to its Gaucher disease drug Elelyso(tm) ...
    12-6-2012
  • Open Innovation in the Pharma Industry
    ... These include the development of 47 lead compounds to treat malaria which have come from open access to the compounds and facilities at GSK's site at Tres Cantos in Spain; Shire ...
    12-4-2012

  • Journal Articles

  • Measurement of Skin Desmosine as an Indicator of Altered Cutaneous...
    Hilde E.V. De Cock, Verena K. Affolter, Thomas B. Farver, Leen Van Brantegem, Brad Scheuch, Gregory L. Ferraro
    Lymphatic Research and Biology
    Lymphatic Research and Biology Background: Chronic progressive lymphedema in Clydesdale and Shire draft horses causes severe disability of the limbs which leads to premature death ...
  • A Long-Term Open-Label Safety and Effectiveness Trial of Lisdexamfetam...
    Robert Findling, Andrew J Cutler, Keith Saylor, Maria Gasior, Mohamed Hamdani, M. Celeste Ferreira-Cornwell, Ann Catherine Childress
    Journal of Child and Adolescent Psychopharmacology
    This study aimed to assess safety and effectiveness of lisdexamfetamine dimesylate (LDX; Vyvanse®, Shire US Inc., Wayne, PA, USA) over 52 weeks in adolescents with ADHD. Methods: ...

GEN Webinars

View »

GEN Web Briefs

View »

GEN Poll

More » Poll Results » Archive »

Genome Sequencing and Patient Autonomy

Do you think ACMG’s recent recommendations for reporting incidental clinical sequencing results undermine patient autonomy?

Suggest a Poll